Endocrine Abstracts

Aim: Low BMD and atherosclerosis may share similar underlying biological mechanisms including higher serum phosphate and inflammation. Neutrophil-lymphocyte ratio (NLR) as a simple marker of inflammation. There are scarce data indicating improved atherosclerosis and cardiovascular events with biphosphonate and teriparatide therapy. We aimed to evaluate NLR before and after 6 months of teriparatide therapy in patients with severe established osteoporosis.

Methods and materials: Electronic data of 53 (49 female, four male) patients with severe osteoporosis and history of fracture of femur neck and/or lumbar spine were evaluated. None of them were previously diagnosed with rheumatoid arthritis, DM, and secondary osteoporosis. Sixteen had with HT and/or other cardiovascular disease.

Results: Mean age was 74±9 years, baseline 25 OH vitamin D level 25.6±17.6 ng/ml, baseline NLR 2.22±0.89, 25 OH vitamin D level at 6th month 27.8±13.4 ng/ml, NLR at 6th month 2.10±0.96.

Mean baseline and 6^th month measurements of NLR, 25 OH vitamin D, parathormone, ALP, ESR, and phosphorus were similar in patients with and without cardiovascular disease. NLR did not change significantly after 6 months of teriparatide therapy.

Conclusion: NLR does not change in short term teriparatide therapy and association between osteoporosis and cardiovascular disease cannot be settled in advanced age.